Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Received Approval of XEGLYZE™ (abametapir) Lotion, 0.74%, in the U.S.
Details : XEGLYZE (Abametapir), contains benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious and fatal adverse reactions including “gasping syndrome” in neonates and low birth weight infants.
Product Name : Xeglyze
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2014
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pediculus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : TKL Research, Inc. | Accelovance
Deal Size : Inapplicable
Deal Type : Inapplicable
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pediculus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2014
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Accelovance | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2014
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ha44 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2013
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2012
Lead Product(s) : Abametapir,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ha44 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2011
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
66
PharmaCompass offers a list of Abametapir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Abametapir manufacturer or Abametapir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Abametapir manufacturer or Abametapir supplier.
PharmaCompass also assists you with knowing the Abametapir API Price utilized in the formulation of products. Abametapir API Price is not always fixed or binding as the Abametapir Price is obtained through a variety of data sources. The Abametapir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DB11932 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DB11932, including repackagers and relabelers. The FDA regulates DB11932 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DB11932 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DB11932 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DB11932 supplier is an individual or a company that provides DB11932 active pharmaceutical ingredient (API) or DB11932 finished formulations upon request. The DB11932 suppliers may include DB11932 API manufacturers, exporters, distributors and traders.
click here to find a list of DB11932 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DB11932 DMF (Drug Master File) is a document detailing the whole manufacturing process of DB11932 active pharmaceutical ingredient (API) in detail. Different forms of DB11932 DMFs exist exist since differing nations have different regulations, such as DB11932 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DB11932 DMF submitted to regulatory agencies in the US is known as a USDMF. DB11932 USDMF includes data on DB11932's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DB11932 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DB11932 suppliers with USDMF on PharmaCompass.
DB11932 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DB11932 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DB11932 GMP manufacturer or DB11932 GMP API supplier for your needs.
A DB11932 CoA (Certificate of Analysis) is a formal document that attests to DB11932's compliance with DB11932 specifications and serves as a tool for batch-level quality control.
DB11932 CoA mostly includes findings from lab analyses of a specific batch. For each DB11932 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DB11932 may be tested according to a variety of international standards, such as European Pharmacopoeia (DB11932 EP), DB11932 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DB11932 USP).
